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ABSTRACT
Background and aims Varenicline and nicotine replacement therapy (NRT) are the most commonly used medications
to quit smoking. Given their widespread use, monitoring adverse risks remains important. This study aimed to estimate the
neuropsychiatric and cardiovascular risks associatedwith varenicline andNRTas used in routine UK care.Design Case–
cross-over study. Setting UK-based electronic primary care records in the Clinical Practice Research Datalink from 2006
to 2015 linked to hospital and mortality data sets. Participants Adult smokers observed during periods when exposed
and not exposed to either varenicline or NRT. Measurements Main outcomes included suicide, self-harm, myocardial
infarction (MI), all-cause death and cause-specific death [MI, chronic obstructive pulmonary disease (COPD)]. In primary
analyses, conditional logistic regression was used to compare the chance of varenicline or NRT exposure during the risk
period (90 days prior to the event) with the chance of exposure during an earlier single reference period (91–180 days
prior to the event) or multiple 90-day reference periods to increase statistical power. Findings In the primary analyses,
findings were inconclusive for the associations between varenicline and themain outcomes using a single reference period,
while NRT was associated with MI [odds ratio (OR) = 1.40, 95% confidence interval (CI) = 1.18–1.67]. Using multiple
reference periods, varenicline was associated with an increased risk of self-harm (OR = 1.32, 95% CI = 1.12–1.56) and
suicide (OR = 3.56, 95% CI = 1.32–9.60) but a reduction in all-cause death (OR = 0.75, 95% CI = 0.61–0.93). NRT
was associated with MI (OR = 1.54, 95% CI = 1.36–1.74), self-harm (OR = 1.30, 95% CI = 1.18–1.44) and deaths from
MI (OR = 1.53, 95% CI = 1.11–2.10), COPD (OR = 1.33, 95% CI = 1.14–1.56) and all causes (OR = 1.28, 95%
CI = 1.18–1.40) when using multiple reference periods. Conclusions There appear to be positive associations between
(1) nicotine replacement therapy (NRT) and myocardial infarction, death and risk of self-harm and (2) varenicline and in-
creased risk of self-harm and suicide, as well as a negative association between varenicline and all-cause death. The asso-
ciations may not be causal. They may reflect health changes at the time of smoking cessation (nicotine replacement
therapy is prescribed for people with cardiac problems) or be associated with quit attempts (exposure to both medicines
was associated with self-harm).
Keywords Adverse events, cardiovascular, neuropsychiatric, nicotine replacement therapy, observational study,
varenicline.
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INTRODUCTION
Smoking is the leading preventable cause of morbidity and
mortality in many countries [1,2]. Varenicline, bupropion
and nicotine replacement therapy (NRT) are all licensed
as smoking cessation medicines in the United Kingdom;
however, bupropion is much less commonly prescribed
than other medications [3]. Varenicline is the most
effective smoking cessation medicine in monotherapy; a
network meta-analysis of randomized controlled trials
showed that for every 10 smokers who quit with
single-form nicotine replacement therapy (NRT) or
bupropion, approximately 16 would be expected to quit
with varenicline [4]. Consistent findings were reported in
a large prospective cohort study which showed that
patients prescribed varenicline were more likely to be
smoking-abstinent than those prescribed NRT, an
association which persisted for up to 4 years [5]. However,
varenicline has not been shown to be more effective than
combination NRT (for example, nicotine patch plus a
faster-acting form of NRT such as nasal spray, gum or
inhalator [4].
Concerns regarding the cardiovascular and neuropsy-
chiatric safety of varenicline led regulatory agencies to
issue safety warnings about varenicline’s possible adverse
effects [6,7]. From 2009 to 2016, the US Food and Drug
Administration (FDA) required that varenicline carry a
Black Box warning on its product labelling; this is the
agency’s strongest safety warning [6]. Although the Black
Box warning was removed by the FDA in December 2016
[8], concerns about varenicline persist among some.
Coroners have linked varenicline to several suicides in
Australia; the FDA’s decision to downgrade the safety
warning has also been criticized [9]. Concerns have also
been raised previously concerning the relationship
between NRT and serious cardiovascular adverse events
in older studies [10,11]. These findings have not been
supported by a recent Cochrane Review, which found little
evidence that NRT increased the risk of MI, although it
increased the odds of chest pains and palpitations relative
to control [12].
Various study designs with differing strengths and
limitations [13] have been used to investigate these safety
issues, including case reports, observational cohort studies
and meta-analyses. Whereas studies using data from
spontaneous reporting systems have reported an increase
in psychiatric adverse effects such as suicide with
varenicline use [14], large observational studies,
randomized controlled trials (RCTs), meta-analyses and
network meta-analyses of RCTs have not supported these
findings [4,15–24]. Additionally, large meta-analyses have
provided conflicting evidence regarding whether patients
prescribed varenicline are at increased risk of adverse
cardiovascular events such as myocardial infarction
[25–28]. Similarly, there are conflicting reports regarding
the cardiovascular safety of NRT. A meta-analysis by Mills
et al. found that NRT was associated with an elevated risk
of chest pain and heart palpitations [29]. However, their
more recent networkmeta-analysis found no evidence that
NRT was associated with major adverse cardiovascular
events, although an elevated risk was observed for all car-
diovascular events, including less serious events such as
heart palpitations [28]. A 2018 Cochrane Review reported
similar findings [12].
There are concerns regarding the validity of
findings using different study designs. First, although
RCTs are considered the gold standard for the evaluation
of the intended effects of medicines, they are rarely
powered or designed to detect rare unintended adverse
effects. Although one of the key aims of meta-analyses
is to combine data from multiple trials and, in
effect, increase the sample size, the sample size require-
ments for rare outcomes, e.g. suicide, may still be
prohibitively large [30]. Secondly, although observational
pharmacoepidemiological studies that utilize large pri-
mary care databases are more likely to meet the sample
size requirements for identifying rare adverse outcomes,
they are prone to residual or uncontrolled confounding,
in particular confounding by indication. Confounding by
indication may arise because individuals who are pre-
scribed a particular medication are likely to differ from
those who are not prescribed the drug, because there
is a reason or indication for prescribing a drug [31].
For example, the use of smoking cessation medicines
may appear to be associated with an increased risk of
cardiovascular disease. However, smoking itself is a ma-
jor risk factor for cardiovascular disease. One approach
to overcoming confounding by indication is to compare
rates of adverse events in patients prescribed different
drugs to treat the same underlying condition (i.e. use
of active comparators) [32].
Epidemiological study designs which rely only on cases,
known as case-only designs, are increasingly used to avoid
pitfalls such as confounding and selection bias, which may
occur in observational studies with control groups such as
cohort and case–control studies [33]. Case-only designs
(which include the case–cross-over method, case–time
control method and self-controlled case–series)may benefit
from the elimination of time-invariant within-person con-
founding factors such as socio-economic position and ge-
netic predisposition. Other benefits include having greater
statistical power to detect rare adverse effects and being less
costly to carry out compared with conventional observa-
tional studies [33].
In the current study, we estimate the neuropsychiatric
and cardiovascular adverse risks of varenicline and NRT
in the UKClinical Practice Research Datalink (CPRD) using
a case–cross-over study design.
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METHODS
Study design and patients
The CPRD is one of the largest primary care databases in
the world and contains electronic medical records from
> 15 million individuals, who are representative of the
UK population [34]. In the United Kingdom > 98% of
the population are registered with a general practitioner
(GP), who act as gatekeepers of care for the National
Health Service. Data fromGP consultations as well as infor-
mation which is fed back from secondary care referrals are
routinely entered onto computers, creating the electronic
medical records of which the CPRD is comprised. We used
data from the CPRD and linked hospital admissions data
from the Hospital Episode Statistics (HES) database and
mortality data from the Office of National Statistics (ONS)
mortality data set to conduct a population-based case–
cross-over study. The case–cross-over method is a type of
case-only design which is epidemiologically and statisti-
cally comparable to matched case–control analyses, except
the case serves as his/her own control [35–37]. In the sim-
plest design, study participants are compared at two differ-
ent time-points (see Fig. 1); the first time-point is nearer to
the occurrence of the event of interest (referred to as the
risk period); the second-time point represents a similar
time-interval occurring further away from and earlier than
the event of interest (referred to as the reference period).
Therefore, if a particular treatment were actually associ-
ated with a specific outcome, it would be expected that ex-
posure to that treatment would occur more frequently
during the risk period than the reference period. The simi-
larity of the case–cross-over study to the matched case–
control design occurs as only discordant pairs (i.e. those ex-
posed during the risk period but not the reference period
and vice versa) contribute to the statistical analysis. Indi-
viduals with concordant matched pairs (i.e. exposed or un-
exposed to treatment during both time-periods) are
uninformative.
All hypotheses and analyses (with the exception of the
analyses exploring time-dependent confounding) were
pre-specified in a study protocol which was approved by
the Independent Scientific Advisory Committee (ISAC)
(http://research-information.bristol.ac.uk/en/persons/ky
la-h-thomas(e3917519-6a48-4192-af81-a1199d545
b40)/projects.html; last accessed 18 March 2020). We
used the most recent version of CPRD Gold available at
the time (November 2015).
Participants
Patients were included if they were adult smokers from 1
September 2006 (when varenicline was licensed in the
United Kingdom) onwards to 31November 2015. Smokers
were defined as patients who have a smoking record which
indicates current smoker (obtained from the ‘Additional
Clinical Details’ file in the CPRD) or Read codes, which in-
dicate current smoking after 1 September 2006. Read
codes are a coded thesaurus of clinical terms which are
used in electronic health-care records in the UK National
Health Service. Read code algorithms to define smoking
status were based on those used in a previous study by
Szatkowski &McNeill in The Health Improvement Network
(THIN) database, which is similar to the CPRD [38]. The
prevalence of current smoking identified from primary care
electronic health records has previously been shown to ac-
curately reflect the prevalence reported in national sur-
veys, such as the Health Survey for England [39].
Records from patients classified as ‘acceptable’ by the
CPRD from all up-to-standard practices at least 18 months
prior to date of entry of each cohort (1 January 2005) were
included. Patient data were defined as ‘acceptable’ by the
CPRD if they met minimum quality control standards; for
example, they had information on sex, date of birth and
first registration with no breaks in registration, i.e. a valid
GP registration period. Up-to-standard practices included
those which reported when their patients first registered
FIGURE 1 Case–cross-over analysis illustrating risk and reference periods and exposure to treatment. ‘X’ represents exposure to a particular treat-
ment. Concordance occurs where there is exposure to treatment in both periods or exposure in neither periods. Discordance occurs where there is
exposure to treatment in the risk period but not the reference period or exposure in the reference period but not the risk period
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with the practice and left the practice, with continuous
data reporting in between.
Patients were excluded if they were registered at a GP
practice for fewer than 365 days before the first recorded
prescription. We excluded patients prescribed both NRT
and varenicline at the same time. In a previous CPRD anal-
ysis, this occurred for 0.25% of all prescriptions [18].
Exposures, outcomes and covariates
Cases included smokers who had experienced one of the
following smoking-related outcomes: suicide, non-fatal
self-harm (suicide attempt), myocardial infarction (MI)
and death from all causes and the following specific causes:
MI, lung cancer and chronic obstructive pulmonary dis-
ease (COPD) (the latter were included as major causes of
smoking-related morbidity and mortality). CPRD Read
codes were used to identify self-harm and MI using vali-
dated algorithms [40,41]. HES data were used to identify
inpatient hospital admissions for self-harm. Deaths were
identified using ONS mortality data. We used linked ONS
mortality data to identify MI deaths, as previous research
has shown that failure to do so may result in biased esti-
mates of MI incidence and outcome [41]. Similarly, CPRD
recording of suicide has also been shown to be unreliable,
although the under-reporting of self-harm is less marked
[40]. The following International Classification of Disease
Tenth Revision (ICD-10) codes were used for mortality:
MI (codes I21–I22), COPD (codes J40–J44), lung cancer
(C34, C78, D02.2, D14.3, D38.1), suicide (intentional
self-harm, codes X60–X84) and events of undetermined at-
tempt, codes Y10–Y34). In England and Wales, the ONS
definition of suicides includes deaths given an underlying
cause of intentional self-harm, in addition to deaths caused
by injury or poisoning where the intent was undetermined
for those aged 15 years and over. This is because most un-
determined deaths are likely to be suicides [42]. Inpatient
self-harm admissions were identified using the same
ICD-10 codes that were used to identify suicide deaths.
Only incident events were included in the statistical analy-
sis. Events were assumed to be independent.
Exposure to varenicline or NRT in the CPRD was iden-
tified using product codes. A product code is a unique code
in the CPRD which is used to identify each specific pre-
scribed medicine selected by a GP for treatment. Product
codes are available from the ‘Therapy file’ of the CPRD.
Statistical analysis
Primary analysis
For the primary analysis, the risk period was defined as
90 days prior to a specific outcome, while the reference pe-
riod was defined as 91–180 days prior to the outcome. A
time-period of 90 days was chosen as the risk period, as
the maximum recommended treatment duration for
varenicline is 12 weeks (3 months) (https://bnf.nice.org.
uk/drug/varenicline.html; last accessed 18 March 2020).
NRT treatment for smoking cessation should also continue
for up to 3 months before dose reduction (https://bnf.nice.
org.uk/drug/nicotine.html#indicationsAndDoses; last
accessed 18 March 2020). If a study participant was ex-
posed to a particular smoking cessation medicine for at
least 1 day in a given reference or risk period, the person
was considered exposed to that medicine for the entire du-
ration of that period. All analyses were repeated replacing
exposure to varenicline with exposure to NRT. NRT was
used as a comparator, as its mechanism of action is differ-
ent from varenicline; the association of both medicines
with a specific adverse event could therefore imply the
event was associated with the timing of smoking cessation
instead of a causal effect of themedication.While the case–
cross-over method deals with time-invariant confounding,
time-varying confounding remains a problem which this
approach could potentially address indirectly.
Each study participant formed two halves of a matched
pair, comparing exposure to varenicline during the risk pe-
riod (90 days prior to the outcome event) with exposure to
varenicline during a single reference period (90 days before
the risk period). Conditional logistic regression was used to
calculate odds ratios (ORs) and 95% confidence intervals
(CIs) for the discordantmatched pairs using the clogit com-
mand. Analyses were carried out using Stata statistical
software version 14MP.
Secondary (sensitivity) analyses
Sensitivity analyses were repeated 30 and 180 days prior
to the event as the risk period, such that the reference pe-
riods were 31–60 days prior to the event and 181–
360 days prior to the event.
Multiple reference periods
Multiple reference periods were used to increase the statis-
tical power of the primary and secondary analyses. This in-
volved using up to a maximum of four reference periods
compared to one risk period. For example, in the primary
analysis, exposure to varenicline during the risk period
(90 days prior to the event) was compared with exposure
to varenicline during four 90-day reference periods (i.e.
91–180, 181–270, 271–360 and 361–450 days prior to
the event).
Assessment of time-dependent confounding
Case–cross-over designs assume no unmeasured
time-dependent confounding. We investigated the possi-
bility of time-dependent confounding in a post-hoc ex-
ploratory analysis by estimating the rates of four
events: primary care diagnoses and hospitalization for
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myocardial infarction and self-harm. Primary care diag-
noses were identified using Read codes in the CPRD.
Hospital admissions were identified using the linked hos-
pital admissions data set using the previously described
ICD-10 codes for self-harm and MI. We performed this
by extracting the weekly number of records indicating
each of the four events during the year before and the
year after the patients were prescribed any NRT or
varenicline prescription. This means that there are mul-
tiple prescriptions per person and the denominator for
this analysis is all NRT or varenicline prescriptions. We
set week zero to be the week before the index prescrip-
tion. We then plotted the event rate by dividing the
number of events per week by the number of NRT and
varenicline prescriptions.
Data statement. Data used in the project are available from
a third party, the Clinical Practice Research Datalink (con-
tact info enquiries@cprd.com). The data can be accessed
by submitting an application to the Independent Scientific
Advisory Committee (https://cprd.com/Data-access). Ethi-
cal approval was not required for this project.
RESULTS
The baseline characteristics (median age and sex) of partic-
ipants experiencing events (excluding lung cancer) are
shown in Table 1. A flow-chart of the number of patients
and prescriptions assessed for eligibility and the reasons
for exclusion is presented in Supporting information, Fig.
S1. The number of events for each outcome is shown in
Table 2. Lung cancer deaths were excluded from further
analysis due to the very small number of events identified.
For the majority of patients dying from lung cancer, NRT
was not prescribed during either the risk or the reference
periods; for varenicline this was the case for all lung cancer
deaths. NRTwas prescribed during the reference period but
not the risk period for < 5 lung cancer deaths.
Table 2 also shows the association between adverse
events in smokers and exposure to varenicline or NRT
using 90-day risk, and up to a maximum of four reference
periods.
Single reference period
For a single 90-day risk period compared to the immedi-
ately preceding 90-day reference period there was incon-
clusive evidence that varenicline was associated with an
increased risk of self-harm (OR = 1.07, 95% CI = 0.85–
1.35); while the risk of suicide was elevated, estimates were
imprecise and confidence intervals spanned the null value
(OR = 3.50, 95% CI = 0.73–16.85). There was inconclu-
sive evidence of an association between varenicline and
self-harm hospital admissions (OR = 0.86, 95%
CI = 0.61–1.23), deaths from MI (OR = 0.80, 95%
CI = 0.32–2.03) or COPD (OR = 0.92, 95% CI = 0.53–
1.61]). There was a positive association between NRT
and MI (OR = 1.40, 95% CI = 1.18–1.67), with inconclu-
sive evidence for other outcomes.
Multiple reference periods
When multiple 90-day reference periods were used with a
single 90-day risk period to increase statistical power, there
was evidence that varenicline was associated with an in-
creased risk of self-harm (OR = 1.32, 95% CI = 1.12–
1.56) and a more than threefold increased risk of suicide
(OR = 3.56, 95% CI = 1.32–9.60). However, varenicline
was associated with a reduction in deaths from all causes
(OR = 0.75, 95% CI = 0.61–0.93). NRT was associated
with an increased risk of MI (OR = 1.54, 95% CI = 1.36–
1.74), self-harm (OR =1.30, 95% CI = 1.18–1.44), MI
deaths (OR = 1.53, 95% CI = 1.11–2.10), COPD deaths
(OR = 1.33, 95% CI = 1.14–1.56) and all-cause deaths
(OR = 1.28, 95% CI = 1.18–1.40). There was inconclusive
evidence for an association of NRT with suicide

















All 19 664 3461 25 455 12 584 679 8730 51
786
% female 30.9 36.4 55.5 54.7 25 44.8 44.2
Median age in
years
65 75 36 37 45 77 75
Abbreviation: COPD = chronic obstructive pulmonary disease.
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(OR = 1.32, 95% CI = 0.69–2.53) or self-harmhospital ad-
missions (OR = 1.08, 95% CI = 0.92–1.26).
Sensitivity analyses
Secondary (sensitivity) analyses using 30- and 180-day
risk and reference periods are shown in Supporting
information, Tables S2 and Table S3, respectively, and
were largely consistent with the findings of the multiple
reference period analyses. Using a 30-day risk and
reference period, varenicline was associated with a
reduced risk of all-cause mortality. NRT was associated
with an increased risk of MI. For the 180-day risk and
reference periods, varenicline was associated with a re-
duction in all-cause mortality and COPD deaths and an
increased risk of MI, self-harm and inpatient self-harm
admissions (using multiple reference periods only). NRT
was associated with an increased risk of MI and self-
harm. However, NRT was also associated with an in-
crease in MI deaths and all-cause mortality (using multi-
ple reference periods).
Figure 2 illustrates the rate of primary care diagnoses of
and hospital admissions for myocardial infarction during
the 52 weeks before and after varenicline and NRT pre-
scriptions. Negative values on the x-axis indicate the weeks
before the prescription, positive values indicate the weeks
after the prescription. There was a significant increase in
the number of diagnoses of MI events during the weeks
leading up to a NRT prescription (from 1.2 MI events per
1000 prescriptions 52 weeks before being prescribed NRT
to 15.7 events per 1000 prescriptions during the week be-
fore being prescribed NRT), followed by a very substantial




Number exposed risk period but not
exposed reference period
Number not exposed risk period but
exposed reference period
OR (95% CI)
1 : 1 matching
OR (95% CI)
1 : 4a matching
Varenicline
































































Matching on amaximum of four 90-day reference (reference) periods to increase statistical power. Non-null findings are shown in bold type. MI =myocardial
infarction; OR = odds ratio; CI = confidence interval; NRT = nicotine replacement therapy; COPD = chronic obstructive pulmonary disease.
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fall in the number of diagnoses during the weeks following
a prescription (from 14.1 events per 1000 during the week
of being prescribed NRT to between 1 and 1.5 events per
1000 from the fourth week after being prescribed NRT on-
wards). The results were similar for the relationship be-
tween hospital admissions for myocardial infarction and
NRT prescribing. A similar temporal trend was observed
with varenicline prescriptions, although it was much less
marked. These findings may be due to non-fatal cardiovas-
cular events or symptoms triggering prescriptions; in our
analyses, prescription of a smoking cessation product is
likely to be affected by within-individual time-dependent
confounding.
Figure 3 illustrates the event rates per 1000 prescrip-
tions for primary care diagnosis and hospital admissions
for self-harm. There were much smaller changes in the
event rate per 1000 prescriptions for self-harm events
compared with MI events over time. Overall, there were
small changes in the self-harm event rates before and af-
ter NRT prescriptions were issued (event rates were con-
sistently between 0.6 and 0.7 per 1000 prescriptions).
However, self-harm events per 1000 prescriptions were
markedly lower during the weeks before a varenicline
prescription (0.1–0.2 events per 1000) compared with
the weeks following a varenicline prescription (0.3–0.6
events per 1000), showing that varenicline was less likely
to be issued if the patient had a recent primary care diag-
nosis of self-harm, consistent with prescribing guidelines.




In the primary analysis using a single 90-day risk period
and reference period we found inconclusive evidence that
FIGURE 2 Rate of myocardial infarction (MI) events and hospital admissions per 1000 prescriptions in the weeks before and after being prescribed
varenicline or nicotine replacement therapy
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varenicline increased the risk of any of our outcomes of
interest. Although NRT was associated with a 40%
(95% CI = 18–67%) increased risk of MI there was
strong evidence of time-dependent confounding, suggest-
ing that MI (or heart disease more generally) may lead
to the prescription of NRT. Findings were also sensitive
to design decisions. When multiple 90-day reference pe-
riods were used to increase statistical power, varenicline
was associated with a 256% (95% CI = 32–860%) in-
creased risk of suicide, 32% increased risk of self-harm
and a 25% reduction in all-cause mortality. Similarly,
NRT was associated with an increased risk of self-harm
and deaths from all-causes, MI and COPD. There was in-
conclusive evidence of an increased risk of self-harm hos-
pital admissions with varenicline or NRT. In the
secondary analyses, varenicline was associated with a
reduction in all-cause deaths using the shorter 30-day
time window for the risk and reference periods and
NRT was associated with an increased risk of MI. How-
ever, using multiple reference periods and the 180-day
risk and reference periods, positive associations were ob-
served for MI and self-harm (varenicline and NRT),
self-harm hospital admissions (varenicline only) and
deaths from MI and all causes (NRT only).
Strengths and limitations
The use of data from the CPRD is one of the main
strengths of this study. Study participants are likely to
be more representative of patients prescribed smoking
cessation medicines in the United Kingdom compared
with the highly selected patients usually included in
FIGURE 3 Rate of self-harm events and hospital admissions per 1000 prescriptions in the weeks before and after being prescribed varenicline or
nicotine replacement therapy
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randomized controlled trials. Secondly, we used validated
code lists and linked data sets to improve the accuracy of
detection of our outcomes of interest [40,41]. Thirdly, we
used the case–cross-over method to investigate the asso-
ciation of varenicline and NRT with adverse outcomes.
Advantages of this study design include its ability to
completely control for between-person confounding, min-
imizing within-person time-invariant confounding factors
(i.e. subject characteristics that remain constant) and
statistical efficiency (the use of multiple reference periods
for one risk period increases statistical power) [35]. Also,
as we investigated varenicline as well as NRT, we could
assess whether events may have resulted from nicotine
withdrawal (e.g. the increased risk of self-harm events
observed with both treatments during the 90-day risk
and reference period when multiple reference periods
were used).
A major study limitation is the observational study de-
sign. Therefore, the analysis was still prone to residual
time-variant confounding, in particular within-person
confounding by transient factors; for example, changes in
disease severity or comorbid conditions [37]. The result of
within-person comparisons would also be affected by the
choice of comparison periods. We observed strong
time-dependent confounding, shown by the temporal pat-
terns in the occurrence of MI and self-harm-related events
before and after smoking cessation medication prescribing
in the exploratory analyses. Patients were more likely to be
prescribed NRT following a primary care diagnosis of MI
and hospitalization for MI. Patients prescribed varenicline
were less likely to have had a primarycare diagnosis or hos-
pital admission for self-harm during the weeks prior to the
prescription. This may be because GPs were less likely to
prescribe varenicline to patients who have recently self-
harmed. Although we observed an association between
both varenicline and NRT and self-harm events in our pri-
mary analyses using multiple reference periods, we did not
find evidence of any associations with self-harm hospitali-
zations. This may have been caused by a lack of statistical
power, as we identified half as many self-harm hospitaliza-
tions as self-harm events.
We were unable to perform case–time control analyses
as stated in our original protocol as we could not obtain a
sufficient number of matched controls. This would have
allowed statistical adjustments to be made for a common
time trend, such as a change in the prescribing pattern of
the smoking cessation medicines [37]. However, this is un-
likely to be an issue during the short time-periods utilized in
themain analyses. It is important to note that our analyses
were also sensitive to some of our design decisions; for ex-
ample, the number of matching periods and the duration
of the risk and reference periods. In the primary analysis,
the use of multiple reference periods provided a point esti-
mate in a more harmful direction to the result using a
single reference period for MI and self-harmhospital admis-
sions in the varenicline group. Additionally, for both
varenicline and NRT, increases in the length of the risk
and reference periods from 30 to 180 days resulted in a
greater number of positive associations using multiple ref-
erence periods. This may be indicative of a temporal bias
which was not fully accounted for in the analyses; i.e. with
increasing time from the event occurrence, the potential
for time-dependent confounding increases due to changes
in the individual such as changes in health status. This is
suggested by the strong temporal pattern of event rates
we observed around the time smoking cessation medica-
tion was started.
Our analyses were also restricted to products pre-
scribed in primary care (thus excluding patients receiving
smoking cessation products in smoking cessation clinics
or buying over-the-counter NRT from pharmacies). Those
who visit a health-care professional for prescribed medi-
cations are likely to be sicker and to be less affluent or
of a lower socio-economic position compared to those
buying over the counter medicines [43]. Therefore, the
analyses may not be generalizable to the wider popula-
tion of people taking smoking cessation medicines, in-
cluding those obtained over the counter without a
prescription. Additionally, being prescribed medication
does not mean that the patient actually took the medica-
tion. We had no information on treatment compliance or
adherence, but problems with either would tend to bias
results towards a null effect.
Comparison with other case-only studies
Three recent studies have used within-person designs to in-
vestigate the neuropsychiatric and cardiovascular safety of
varenicline [44–46]. Monarrez-Espino et al. carried out a
case–cross-over study using data from Swedish health
and administrative registers [44]. They reported on four
different hazard (risk) periods, including a hazard period
of 1–84 days, which approximates to our main analyses
using a 90-day risk and reference period. There was incon-
clusive evidence that varenicline was associated with MI
(OR = 0.98, 95% CI = 0.80–1.22), suicide (OR = 0.58,
95% CI = 0.32–1.06) or suicide attempt (OR = 0.82,
95%CI = 0.63–1.07). However, vareniclinewas associated
with a reduction in the outcome which combined suicide
and suicide attempt (OR = 0.77, 95% CI = 0.60–0.98).
These findings are not consistent with our study, possibly
due to differences in the study populations or differences
in prescribing behaviour for smoking cessation in Sweden
compared with the United Kingdom, leading to different
temporally associated changes in risk. Gershon et al. used
a self-controlled risk interval study design to investigate
neuropsychiatric and cardiovascular hospitalizations with
varenicline [45]. Similar to the case–cross-over study, each
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patient acts as his/her own control,minimizingwithin-per-
son time-invariant confounding. However, it differs from
the case–cross-over study design, as for patients exposed
to a particular treatment it examines the risk of the out-
come of interest during a specified period closest to the ex-
posure (risk period) with a remaining observation period
(control period). For new users of varenicline, the authors
found a 34% higher incidence of cardiovascular events
during the 12-week risk period compared with the control
interval (relative incidence = 1.34, 95% CI = 1.25–1.44).
An increase in the incidence of neuropsychiatric events
was also observed for varenicline (relative incidence=1.06,
95% CI = 1.00–1.13). This finding is similar to our finding
for the association of varenicline and self-harm in the main
analyses (OR = 1.07, 95% CI = 0.85–1.35). The differ-
ences in the results for cardiovascular outcomes may be
due to the differences in estimation of the risk periods and
population size. The authors did not examine outcomes
in relation to NRT.
Molero et al. used a within-person comparison cohort
design to examine associations between varenicline and a
range of outcomes including new psychiatric conditions
and suicidal behaviour [46]. Although varenicline was
not shown to be associated with suicidal behaviour [hazard
ratio (HR) = 1.00, 95% CI 0.72–1.37], it was associated
with an increase in the risk of anxiety conditions
(HR = 1.27, 95% CI = 1.06–1.51) and mood conditions
(HR= 1.28, 95% CI = 1.07–1.52). Suicidal behaviour
was defined as emergency in- or outpatient hospital visits
or death due to intentional self-harm and differed from
our analyses, as they did not include ICD codes for undeter-
mined events or deaths.
One study examined the use of NRT and the risk of
acute MI, stroke and death in the THIN, using the
self-controlled case series method [47]. The incidence of
MI increased during the 56 days prior to the first prescrip-
tion of NRT [incidence ratio (IR) = 5.55, 95% CI = 4.42–
6.98], although it was not increased during the 56 days
following the first NRT prescription (IR = 1.27, 95%
CI = 0.82–1.97). However, there was an increased risk of
MI during the first 14 days following NRT prescription
(IR = 2.39, 95% CI = 1.28–4.48), which is consistent with
our findings.
Comparison with other study designs
With respect to neuropsychiatric outcomes, our results
from the primary analyses using a single 90-day risk period
and multiple 90-day reference periods are consistent with
prescription event monitoring studies and studies using ad-
verse event reporting databases, which have reported an
increased risk of reported suicidal behaviour for varenicline
compared with NRT [14,48–51]. However, previous stud-
ies which included comparison groups (i.e. RCTs, meta-
analyses of RCTs and other observational study designs)
have reported inconclusive findings as to whether
varenicline is associated with an increased risk of suicide,
suicide attempt or other mental disorders (depression, neu-
rotic disorders or prescriptions for anti-depressants) [15–
22]. This could partly be because most RCTs and
meta-analyses of RCTs would not have sufficient statistical
power to detect an effect of prescribing varenicline on such
a rare outcome [19,21]. For example, the large Evaluating
Adverse Events in a Global Smoking Cessation (EAGLES)
study found no significant increase in neuropsychiatric
events with varenicline compared to placebo or NRT
[21]. The study had a sample size of 8144 participants
among four treatment groups; it was statistically powered
to detect an adverse event which occurred in at least 4%
of patients in any treatment group (a moderate effect size).
However, a sample size of 21 584 would be needed for a
clinical trial to detect the more than threefold increase we
observed for suicide in this study, based on a suicide inci-
dence rate of 9.2 per 100 000 at 80% power and 5% signif-
icance. Previous meta-analyses of neuropsychiatric events
have included < 12 000 participants and reported very
few suicides; therefore, the lack of statistical power to detect
an effect would also be an issue in these studies [19,23].
Previous observational cohort studies which found incon-
clusive evidence between smoking cessation medicines
and neuropsychiatric outcomes or a negative association
were also likely to be impacted by residual confounding
(those prescribed varenicline were healthier than those
prescribed NRT) and/or the very limited numbers of sui-
cides identified (< 0) [15,18,20,24]. Our study found an
association between self-harm and being prescribed NRT
or varenicline, which may be explained by an association
between quit attempts and self-harm. Although nicotine
withdrawal is known to be associated with mood changes
[52], evidence showing a clear association with self-harm
is lacking.
Our findings for all-cause mortality suggest caution is
needed when interpreting results. Varenicline was associ-
ated with a reduction in all-cause mortality, consistent
with findings using conventional methods of analyses
(multivariable regression and propensity score matching)
from previous UK primary care observational studies using
the CPRD and the Q Research database [18,20]. The pro-
tective effect of varenicline on all-cause mortality was not
driven solely by a reduction in COPD or MI deaths. How-
ever, we were unable to identify the specific causes behind
this protective effect, as our CPRD extract did not include
causes of death we had not prespecified in our protocol.
Conversely, we found that NRT was associated with higher
all-cause mortality in our primary analyses using a single
90-day risk period and multiple 90-day reference periods.
However, it is possible that all the analyses may have been
affected by time-dependent residual confounding.
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Additionally, previous studies have shown that people pre-
scribed varenicline are likely to be healthier than those pre-
scribed NRT [15,18,20].
Findings regarding the cardiovascular safety of
varenicline are also conflicting. In this study, varenicline
was only associated with an increased risk of MI events
for the 180-day risk and reference period using multiple
reference periods. Although a 19% increased risk of MI
events was observed during the 90-day risk and reference
periods, the 95% CI included the null. Previous studies (in-
cluding the EAGLES study and its non-treatment extension
[53], meta-analyses of RCTs [26,28] and an observational
study [20]) found no increase in cardiovascular events
with varenicline or NRT. However, a systematic review of
varenicline versus placebo found evidence of an increased
risk [25]. The Mills et al. (networkmeta-analysis also found
an elevated risk of cardiovascular events associated with
NRT, mainly due to less serious events, but was underpow-
ered to assess the risk of serious events [28]. A recent co-
hort study using the CPRD also found an increase in
cardiovascular events by 52 weeks for patients prescribed
NRT compared with those receiving smoking cessation ad-
vice only [54]. These findings are consistent with our
study. This association may be due to smokers who experi-
ence worsening of symptoms, such as chest pain, being
more likely to seek help from their GPs to quit smoking
(as shown by Fig. 2).
CONCLUSIONS
In this study, we used a case–cross-over study design to
investigate the risk of neuropsychiatric and cardiovascu-
lar outcomes associated with varenicline and NRT in a
real-world setting. For primary analyses using a 90-day
risk period and multiple reference periods, we observed
associations between varenicline and suicide and
self-harm as well as associations between NRT and self-
harm, MI, MI deaths and all-cause mortality. However,
these temporal associations may not be causal, as we also
found strong evidence of time-dependent confounding,
particularly for our NRT analyses where those experienc-
ing MI were likely to be prescribed NRT during the week
before the event. The evidence was much less marked for
varenicline. The association of both varenicline and NRT
with self-harm in our study may reflect an association be-
tween self-harm and quit attempts, rather than a causal
association with the smoking cessation medications. Ad-
ditionally, associations such as a reduction in all-cause
mortality with varenicline and an increased risk of COPD
deaths with NRT may be explained by differences in GP
prescribing behaviour (healthier patients are prescribed
varenicline) or changes in health status (for example,
COPD exacerbation triggering NRT prescribing). Further
evidence will be provided when the results of the largest
network meta-analysis of smoking cessation medicines
and e-cigarettes are reported [55]. The study will report
on smoking abstinence in addition to safety outcomes, in-
cluding serious adverse events, major adverse neuropsy-
chiatric events (including suicide and self-harm) and
major adverse cardiovascular events. Further research
can aim to replicate our study using similar data sets;
for example, Scandinavian record linkage studies and
large North American health-care databases. Addition-
ally, mendelian randomization and genetic correlation
studies may provide further information on associations
with self-harm. What is clear is that, regardless of cause,
people attempting to stop smoking with smoking cessa-
tion therapies appear to have a higher risk of neuropsy-
chiatric and cardiorespiratory events which may be due
to time-dependent confounding (people who are sicker
seeking treatment), or theoretically an effect of taking
smoking cessation therapy. More research is needed to
elucidate these relationships.
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